Histone Deacetylase Modifications by Probiotics in Colorectal Cancer

被引:32
|
作者
Salek Farrokhi, Amir [1 ]
Mohammadlou, Maryam [1 ]
Abdollahi, Maryam [1 ]
Eslami, Majid [2 ]
Yousefi, Bahman [1 ]
机构
[1] Semnan Univ Med Sci, Dept Immunol, Semnan, Iran
[2] Semnan Univ Med Sci, Canc Res Ctr, Semnan, Iran
关键词
Colorectal cancer; Epigenetic; Histone deacetylase; Probiotic; HDAC INHIBITORS; CELLS; ACETYLATION; APOPTOSIS; MICROBIOME; EXPRESSION; MOLECULES; CHROMATIN; MICRORNAS; DIFFERENTIATION;
D O I
10.1007/s12029-019-00338-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has been demonstrated that epigenetic modifications of histone (acetylation/deacetylation) participate in a critical role in cancer progression by the regulation of gene expression. Several processes could be regulated by deacetylation of histone and non-histone proteins such as apoptosis, proliferation, cell metabolism, differentiation, and DNA repair. Hence, histone deacetylase inhibitors (HDACis) are employed as a hopeful group of anti-cancer drugs that could inhibit tumor cell proliferation or apoptosis. The elimination of the acetylation marks that take place as an essential epigenetic change in cancer cells is associated to HDAC expression and activity. In this regard, it has been reported that class I HDACs have a vital role in the regulation of tumor cell proliferation. Objectives In this review, we discuss whether gut origin microorganisms could promote cancer or tumor resistance and explain mechanisms of these processes. Conclusions According to the enormous capacity of the metabolism of the intestine microbiota, bacteria are likely to convert nutrients and digestive compounds into metabolites that regulate epigenetic in cancer. The effect of the food is of interest on epigenetic changes in the intestinal mucosa and colonocytes, as misleading nucleotide methylation may be a prognostic marker for colorectal cancer (CRC). Since epigenetic changes are potentially reversible, they can serve as therapeutic targets for preventing CRC. However, various mechanisms have been identified in the field of prevention, treatment, and progression of cancer by probiotics, which include intestinal microbiota modulation, increased intestinal barrier function, degradation of potential carcinogens, protective effect on intestinal epithelial damage, and increased immune function.
引用
收藏
页码:754 / 764
页数:11
相关论文
共 50 条
  • [1] Histone Deacetylase Modifications by Probiotics in Colorectal Cancer
    Amir Salek Farrokhi
    Maryam Mohammadlou
    Maryam Abdollahi
    Majid Eslami
    Bahman Yousefi
    [J]. Journal of Gastrointestinal Cancer, 2020, 51 : 754 - 764
  • [2] Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer
    Vuletic, Ana
    Martinovic, Katarina Mirjacic
    Spasic, Jelena
    [J]. PHARMACEUTICS, 2024, 16 (01)
  • [3] Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?
    Tampakis, Athanasios
    Tampaki, Ekaterini C.
    Nebiker, Christian A.
    Kouraklis, Gregory
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (09) : 1220 - 1227
  • [4] Histone Modifications and their Role in Colorectal Cancer (Review)
    Qin, Jingchun
    Wen, Bin
    Liang, Yuqi
    Yu, Weitao
    Li, Huixuan
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2023 - 2033
  • [5] The histone deacetylase complex as a drugable target in colorectal cancer.
    Mayer, Barbara
    Ilmberger, Christian
    Halfter, Kathrin
    Joka, Mareile
    Heinemann, Volker
    Werner, Jens
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Targeting euchromatic histone lysine methyltransferases sensitizes colorectal cancer to histone deacetylase inhibitors
    Bamberg, Leonhard Valentin
    Heigwer, Florian
    Wandmacher, Anna Maxi
    Singh, Ambika
    Betge, Johannes
    Rindtorff, Niklas
    Werner, Johannes
    Josten, Julia
    Skabkina, Olga Valerievna
    Hinsenkamp, Isabel
    Erdmann, Gerrit
    Roecken, Christoph
    Ebert, Matthias P.
    Burgermeister, Elke
    Zhan, Tianzuo
    Boutros, Michael
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (09) : 1586 - 1601
  • [7] Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer
    Alzoubi, Samer
    Brody, Leigh
    Rahman, Sunniyat
    Mahul-Mellier, Anne-Laure
    Mercado, Nicolas
    Ito, Kazuhiro
    El-Bahrawy, Mona
    Silver, Andrew
    Boobis, Alan
    Bell, Jimmy D.
    Hajji, Nabil
    [J]. ONCOTARGET, 2016, 7 (28) : 44505 - 44521
  • [8] In Vitro Evaluation of Histone Deacetylase Inhibitors as Combination Agents for Colorectal Cancer
    Kim, Jin C.
    Shin, Eui S.
    Kim, Chan W.
    Roh, Seon A.
    Cho, Dong H.
    Na, Young S.
    Kim, Tae W.
    Kim, Moon B.
    Hyun, Young L.
    Ro, Seonggu
    Kim, Seon Y.
    Kim, Yong S.
    [J]. ANTICANCER RESEARCH, 2009, 29 (08) : 3027 - 3034
  • [9] Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer
    Benard, Anne
    Goossens-Beumer, Ines J.
    van Hoesel, Anneke Q.
    Horati, Hamed
    de Graaf, Wouter
    Putter, Hein
    Zeestraten, Eliane C. M.
    Liefers, Gerrit-Jan
    van de Velde, Cornelis J. H.
    Kuppen, Peter J. K.
    [J]. HISTOPATHOLOGY, 2015, 66 (02) : 270 - 282
  • [10] Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects
    Singh, Avineesh
    Patel, Preeti
    Patel, Vijay K.
    Jain, Deepak K.
    Veerasamy, Ravichandran
    Sharma, Prabodh C.
    Rajak, Harish
    [J]. CURRENT CANCER DRUG TARGETS, 2017, 17 (05) : 456 - 466